GenMark Diagnostics, Inc. (NASDAQ:GNMK) CFO Scott Mendel sold 2,898 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $9.45, for a total value of $27,386.10. Following the completion of the transaction, the chief financial officer now owns 138,096 shares of the company’s stock, valued at $1,305,007.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Scott Mendel also recently made the following trade(s):

  • On Tuesday, August 15th, Scott Mendel sold 1,752 shares of GenMark Diagnostics stock. The stock was sold at an average price of $10.16, for a total value of $17,800.32.
  • On Wednesday, August 2nd, Scott Mendel sold 333 shares of GenMark Diagnostics stock. The stock was sold at an average price of $10.33, for a total value of $3,439.89.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) traded down 2.48% on Friday, hitting $9.44. The stock had a trading volume of 63,603 shares. GenMark Diagnostics, Inc. has a 12 month low of $8.03 and a 12 month high of $13.67. The company’s market cap is $516.06 million. The company has a 50-day moving average of $10.96 and a 200 day moving average of $12.06.

GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by $0.05. GenMark Diagnostics had a negative return on equity of 109.89% and a negative net margin of 111.96%. The firm had revenue of $12.36 million for the quarter, compared to analyst estimates of $12.44 million. During the same quarter last year, the company earned ($0.30) earnings per share. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, analysts predict that GenMark Diagnostics, Inc. will post ($1.07) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/25/scott-mendel-sells-2898-shares-of-genmark-diagnostics-inc-gnmk-stock.html.

GNMK has been the subject of a number of research reports. Needham & Company LLC increased their target price on GenMark Diagnostics from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, June 13th. Canaccord Genuity reiterated a “buy” rating and set a $17.00 target price on shares of GenMark Diagnostics in a research report on Monday, June 12th. Cowen and Company reiterated an “outperform” rating and set a $17.00 target price on shares of GenMark Diagnostics in a research report on Wednesday, August 2nd. ValuEngine upgraded GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Zacks Investment Research downgraded GenMark Diagnostics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. GenMark Diagnostics currently has a consensus rating of “Hold” and an average target price of $15.80.

Several large investors have recently bought and sold shares of GNMK. FMR LLC boosted its stake in GenMark Diagnostics by 1.4% in the first quarter. FMR LLC now owns 7,057,680 shares of the medical equipment provider’s stock valued at $90,480,000 after buying an additional 97,034 shares during the period. American International Group Inc. raised its position in shares of GenMark Diagnostics by 7.8% in the first quarter. American International Group Inc. now owns 24,885 shares of the medical equipment provider’s stock valued at $319,000 after buying an additional 1,802 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of GenMark Diagnostics by 5.1% in the first quarter. JPMorgan Chase & Co. now owns 3,538,138 shares of the medical equipment provider’s stock valued at $45,359,000 after buying an additional 170,977 shares in the last quarter. Airain ltd bought a new position in shares of GenMark Diagnostics during the first quarter valued at about $159,000. Finally, Ameriprise Financial Inc. bought a new position in shares of GenMark Diagnostics during the first quarter valued at about $435,000. Institutional investors own 93.07% of the company’s stock.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Stock Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related stocks with our FREE daily email newsletter.